Is it time to test biguanide metformin in the treatment of melanoma?

@article{Cerezo2015IsIT,
  title={Is it time to test biguanide metformin in the treatment of melanoma?},
  author={Michael Cerezo and Tijana Vukoji{\vc}i{\'c} Tomi{\'c} and Robert Ballotti and St{\'e}phane Rocchi},
  journal={Pigment cell & melanoma research},
  year={2015},
  volume={28 1},
  pages={8-20}
}
Metformin is the most widely used antidiabetic drug that belongs to the biguanide class. It is very well tolerated and has the major clinical advantage of not inducing hypoglycemia. Metformin decreases hepatic glucose production via a mechanism requiring liver kinase B1, which controls the metabolic checkpoint, AMP-activated protein kinase-mammalian target of rapamycin and neoglucogenic genes. The effects of metformin on this pathway results in reduced protein synthesis and cell proliferation… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 124 references

Cell cycle arrest

  • Y. Zhuang, W. K. Miskimins
  • 2008
Highly Influential
5 Excerpts

Metformin blocks

  • M. Cerezo, M. Tichet, P Abbe
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…